This cost-effectiveness analysis compares nivolumab plus ipilimumab vs sunitinib to examine whether the drug combination is cost-effective from a US payer perspective as a first-line treatment for intermediate- and poor-risk patients with metastatic renal cell carcinoma.
https://ift.tt/2E64gZ4
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου